ProCE Banner Activity

Phase II Trial of Ibrutinib + Venetoclax in Previously Untreated, High-Risk Chronic Lymphocytic Leukemia (CLL)

Slideset Download
Conference Coverage
Ongoing combination therapy achieved improved responses, including in older patients and across all high-risk groups, with 96% and 69% of patients achieving CR/CRi and BM MRD negativity, respectively, at 18 months.

Released: December 12, 2018

Expiration: December 11, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology